Alnylam Pharmaceuticals (ALNY) Retained Earnings (2009 - 2026)

Alnylam Pharmaceuticals has reported Retained Earnings for 18 years, with the latest figure at -$24.9 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings rose 33.65% year-over-year to -$24.9 million; the trailing twelve-month figure through Mar 2026 stood at -$24.9 million (up 33.65% YoY), and the FY2025 full-year result was -$20.1 million, up 41.78% from the prior year.
• Retained Earnings for Q1 2026 stood at -$24.9 million, down from -$20.1 million in the prior quarter.
• The five-year high for Retained Earnings was -$20.1 million in Q4 2025, with the low at -$7.1 billion in Q2 2024.
• Historically, Retained Earnings has averaged -$1.3 billion across 5 years, with a median of -$37.5 million in 2025.
• Annual changes were most pronounced in 2024 — Retained Earnings sank 19027.33% — and 2025, when it surged 99.58%.
• Alnylam Pharmaceuticals' Retained Earnings stood at -$44.7 million in 2022, then slumped by 15597.57% to -$7.0 billion in 2023, then jumped by 99.51% to -$34.5 million in 2024, then surged by 41.78% to -$20.1 million in 2025, then decreased by 23.87% to -$24.9 million in 2026.
• The last three Retained Earnings figures came in at -$24.9 million (Q1 2026), -$20.1 million (Q4 2025), and -$21.8 million (Q3 2025), per Business Quant data.